Forodesine (BCX-1777) in Treating Patients With Refractory Stage IIA, Stage IIB, Stage III, Stage IVA, or Stage IVB Cutaneous T-Cell Lymphoma

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •Histologically confirmed cutaneous T-cell lymphoma
• •* Refractory to prior treatment
• •* Stage IIA, IIB, III, IVA, or IVB disease
• •Measurable disease
• •PATIENT CHARACTERISTICS:
• •Age
• •18 and over
• •Performance status
• •ECOG 0-2
• •Life expectancy
• •At least 3 months
• •Hematopoietic
• •Not specified
• •Hepatic
• •AST and/or ALT ≤ 3 times upper limit of normal
• •Hepatitis B and/or hepatitis C negative
• •Renal
• •Creatinine clearance ≥ 40 mL/min
• •Immunologic
• •Human T-cell lymphotrophic virus type I (HTLV-I) negative
• •HIV negative
• •No active serious infection not controlled by antibiotics
• •Other
• •Not pregnant or nursing
• •Negative pregnancy test
• •Fertile patients must use effective contraception
• •No known impaired absorption of the gastrointestinal tract
• •No other illness that would preclude study participation
• •PRIOR CONCURRENT THERAPY:
• •Biologic therapy
• •Not specified
• •Chemotherapy
• •More than 21 days since prior chemotherapy and recovered
• •Endocrine therapy
• •Concurrent topical corticosteroids allowed provided patient remains on a stable dose
• •Radiotherapy
• •No concurrent radiotherapy
• •Surgery
• •Not specified
• •Other
• •More than 30 days since prior investigational agents and recovered
• •No concurrent tanning bed use
• •No other concurrent therapy for cutaneous T-cell lymphoma